↓ Skip to main content

PLOS

Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial

Overview of attention for article published in PLOS ONE, June 2014
Altmetric Badge

Mentioned by

twitter
3 X users

Citations

dimensions_citation
49 Dimensions

Readers on

mendeley
140 Mendeley
Title
Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial
Published in
PLOS ONE, June 2014
DOI 10.1371/journal.pone.0098426
Pubmed ID
Authors

Lea T. Drye, David Spragg, D. P. Devanand, Constantine Frangakis, Christopher Marano, Curtis L. Meinert, Jacobo E. Mintzer, Cynthia A. Munro, Gregory Pelton, Bruce G. Pollock, Anton P. Porsteinsson, Peter V. Rabins, Paul B. Rosenberg, Lon S. Schneider, David M. Shade, Daniel Weintraub, Jerome Yesavage, Constantine G. Lyketsos

Abstract

A Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 140 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 139 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 24 17%
Researcher 17 12%
Student > Bachelor 16 11%
Other 15 11%
Student > Postgraduate 8 6%
Other 28 20%
Unknown 32 23%
Readers by discipline Count As %
Medicine and Dentistry 42 30%
Neuroscience 10 7%
Nursing and Health Professions 9 6%
Psychology 8 6%
Agricultural and Biological Sciences 6 4%
Other 27 19%
Unknown 38 27%